Monte Rosa Therapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for GLUE, updated each market day.
GLUE AI Sentiment
AI sees no strong directional signal for Monte Rosa Therapeutics, Inc. Common Stock stock over the next 10 market days.
Prediction date: May 20, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Monte Rosa Therapeutics, Inc. Common Stock
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
Sector
Exchange
Market Cap
$1,578,075,528
Cap Tier
Employees
161
Headquarters
BOSTON, MA
Listed Since
June 24, 2021
Website
GLUE Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
GLUE Volatility
Monte Rosa Therapeutics, Inc. Common Stock has shown moderate price volatility over the last 5 trading days. Moderate volatility indicates normal market activity with typical price fluctuations.
